CDKN2A antibody

Catalog No. ABIN6139280

Product Details anti-CDKN2A Antibody

Target: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This CDKN2A antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)

Cross-Reactivity: Human

Characteristics: Monoclonal Antibodies

Purification: Affinity purification

Immunogen: A synthesized peptide derived from human CDKN2A/p16INK4a

Isotype: IgG

Application Details

Application Notes: WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200

Comment:

HIGH QUALITY

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,0.05 % BSA,50 % glycerol, pH 7.3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for CDKN2A

Target: CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A))

Alternative Name: CDKN2A (CDKN2A Products)

Synonyms: Arf antibody, p16 antibody, MTS1 antibody, INK4A antibody, p19ARF antibody, p16Cdkn2a antibody, ARF antibody, CDK4I antibody, CDKN2 antibody, CMM2 antibody, INK4 antibody, MLM antibody, MTS-1 antibody, P14 antibody, P14ARF antibody, P16 antibody, P16-INK4A antibody, P16INK4 antibody, P16INK4A antibody, P19 antibody, P19ARF antibody, TP16 antibody, ARF-INK4a antibody, INK4a-ARF antibody, Ink4a/Arf antibody, Pctr1 antibody, p16(INK4a) antibody, p16INK4a antibody, p19 antibody, cyclin-dependent kinase inhibitor 2A antibody, cyclin dependent kinase inhibitor 2A antibody, Cdkn2a antibody, LOC100731972 antibody, LOC100340625 antibody, CDKN2A antibody

Background: This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene, this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012],ARF, CDK4I, CDKN2, CMM2, INK4, INK4A, MLM, MTS-1, MTS1, P14, P14ARF, P16, P16-INK4A, P16INK4, P16INK4A, P19, P19ARF, TP16,Apoptosis,Cancer,Cell Biology & Developmental Biology,Cell Cycle,Cell Cycle_Cell cycle inhibitors,G1/S Checkpoint,G2/M DNA Damage Checkpoint,Kinase,Signal Transduction,CDKN2A

Molecular Weight: 17 kDa

Gene ID: 1029

UniProt: P42771

Pathways: Mitotic G1-G1/S Phases, Stem Cell Maintenance, Positive Regulation of Endopeptidase Activity, Autophagy, Positive Regulation of Response to DNA Damage Stimulus